P53 and proliferating cell nuclear antigen (PCNA) expression in non- tumoral liver diseases

Pathology International

Volumn 49, Issue 3, 1999, Pages 214-221

  Akyol, Gülen ^a,b   Dursun, Ayse ^a   Poyraz, Aylar ^a   Uluoglu, Ömer ^a   Ataoglu, Ömür ^a   Edalý, Naci ^a   Memis, Leyla ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Immunohistochemistry; Non tumoral liver diseases; p53; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE; DNA; MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; CELL NUCLEUS; CHRONIC HEPATITIS; CONTROLLED STUDY; DNA REPLICATION; FATTY LIVER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER NECROSIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CELL NUCLEUS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER DISEASES; LIVER NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032942644     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.1999.00849.x     Document Type: Article

References (27)

1. Yandell DW, Thor AD. P53 analysis in diagnostic pathology, biologic implications and possible clinical applications. Diagn. Mol. Pathol. 1993; 2; 1-3.
2. Shurbaji MS, Kalbfleisch JH, Thurmonds TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Pathol. 1995; 26: 106-109.
3. Livni N, Eid A, Ilan Y et al. P53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995; 75: 2420-2426.
4. Dalbagni G, Presti JC, Reuter VE et al. Molecular genetic alterations of chromosome 17 and p53 nuclear over-expression in human bladder cancer. Diagn. Mol. Pathol. 1993; 2: 4-13.
5. Yaziji H, Massarani-Wafai R, Gujirati M, Kuhns JG, Martin AW, Parker JC. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am. J. Surg. Pathol. 1996; 20: 1086-1090.
6. Nagao T, Kondo F, Sato T, Nagato Y, Kondo Y. Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: Correlation with cell proliferative activity indices including mitotic index and MIB-1 immunostaining. Hum. Pathol. 1995; 26: 326-333.
7. Kastan MB, Onyekwere O, Sidransky D et al. P53 expression is common in malignant mesothelioma. Histopathology 1992; 21: 331-334.
8. Kuerbitz SJ, Plunkett BS, Walsh WV et al. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA 1992; 89: 7491-7495.
9. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV irradiated normal human skin. Oncogene 1993; 8: 203-207.
10. Kitamoto M, Nakanishi T, Kira S et al. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 1993; 72: 1859-1865.
11. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S-phase. Proc. Natl Acad. Sci. USA 1985; 82: 3262-3266.
12. Hall PA, Levison DA, Woods AL et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasm. J. Pathol. 1990; 162: 285-294.
13. Robbins BA, de la Vega D, Ogata K, Tan EM, Nakamura RM. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch. Pathol. Lab. Med. 1987; 111: 841-845.
14. Takasaki Y, Robinson WA, Tan EM. Proliferating cell nuclear antigen in blast crisis cells of patients with chronic myeloid leukemia. J. Natl Cancer Inst. 1984; 73: 655-661.
15. Murashima A, Takasaki Y, Ohgaki M, Hashimoto H, Shirai T, Hirose S. Activated peripheral blood mononuclear cells detected by murine monoclonal antibodies to proliferating cell nuclear antigen in active lupus patients. J. Clin. Immunol. 1990; 10: 28-37.
16. Mercer WE, Shields MT, Lin D, Appella E, Ullrich SJ. Growth suppression induced by wild type p53 protein is accompanied by selective down regulation of proliferating cell nuclear antigen expression. Proc. Natl Acad. Sci. USA 1991; 88: 1958-1962.
17. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
18. Bianchi L, Gudat F. Chronic hepatitis. In: McSween RM, Anthony PP, Scheuer PJ, Burt AD, Portman BC, eds. Pathology of the Liver, 3rd edn. Churchill Livingstone, Edinburgh, 1994; 349-395.
19. Ojanguren I, Arlza A, Llatjos M, Castella E, Mate JL, Navas- Palacios JJ. Proliferating cell nuclear antigen expression in normal, regenerative and neoplastic liver: A fine needle aspiration cytology and biopsy study. Hum. Pathol. 1993; 24: 905-908.
20. Pezella F, Micklem K, Turley H et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J. Clin. Pathol. 1994; 47: 592-596.
21. Wolf HK, Michalopoulos GK. Hepatocyte regeneration in acute fulminant and non-fulminant hepatitis: A study of proliferating cell nuclear antigen expression. Hepatology 1992; 15: 707- 713.
22. Kawakita N, Seki S, Sakaguchi H et al. Analysis of proliferating hepatocytes using a monoclonal antibody against proliferating cell nuclear antigen/cyclin in embedded tissues from various liver diseases fixed in formaldehyde. Am. J. Pathol. 1992; 140: 513-520.
23. Lin HH, Shyu WC, Chen GL et al. DNA measurements in chronic hepatitis, cirrhosis and hepatocellular carcinoma. Liver 1990; 10: 313-318.
24. Choi SW, Hytiroglou P, Geller SA et al. The expression of p53 antigen in primary malignant epithelial tumors of the liver: An immunohistochemical study. Liver 1993; 13: 172-176.
25. Battifora H. P53 immunohistochemistry: A word of caution. Hum. Pathol. 1994; 25: 435-437.
26. Hall PA, Lane DP. P53 in tumor pathology: Can we trust immunohistochemistry? J. Pathol. 1994; 172: 1-4.
27. Mayall FG, Goddard H, Gibbs AR. P53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J. Pathol. 1992; 168: 377-381.